Abstract

Simple SummaryThere is strong evidence that locally advanced human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) carries a significantly better prognosis than HPV negative OPSCC, suggesting the possibility of treatment de-escalation and, therefore, toxicity reduction in this patient population. The lack of success in clinical trials towards this end presses the need to risk stratify locally advanced HPV+ OPSCC patients who can safely have treatment de-escalated. The present study had recourse to radiomics for this purpose and showed that radiomics has the ability to discriminate patients with locally advanced HPV+ OPSCC who went on to develop distant metastasis after completion of definitive chemoradiation or radiation alone. The implications of this study aid in demonstrating the potential pivotal role of radiomics in predictive risk assessment and personalizing therapy for this patient population.(1) Background and purpose: clinical trials have unsuccessfully tried to de-escalate treatment in locally advanced human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) with the goal of reducing treatment toxicity. The aim of this study was to explore the role of radiomics for risk stratification in this patient population to guide treatment. (2) Methods: the study population consisted of 225 patients with locally advanced HPV+ OPSCC treated with curative-intent radiation or chemoradiation therapy. Appearance of distant metastasis was used as the endpoint event. Radiomics data were extracted from the gross tumor volumes (GTVs) identified on the planning CT, with gray level being discretized using three different bin widths (8, 16, and 32). The data extracted for the groups with and without distant metastasis were subsequently balanced using three different algorithms including synthetic minority over-sampling technique (SMOTE), adaptive synthetic sampling (ADASYN), and borderline SMOTE. From these different combinations, a total of nine radiomics datasets were derived. Top features that minimized redundancy while maximizing relevance to the endpoint were selected individually and collectively for the nine radiomics datasets to build support vector machine (SVM) based predictive classifiers. Performance of the developed classifiers was evaluated by receiver operating characteristic (ROC) curve analysis. (3) Results: of the 225 locally advanced HPV+ OPSCC patients being studied, 9.3% had developed distant metastases at last follow-up. SVM classifiers built for the nine radiomics dataset using either their own respective top features or the top consensus ones were all able to differentiate the two cohorts at a level of excellence or beyond, with ROC area under curve (AUC) ranging from 0.84 to 0.95 (median = 0.90). ROC comparisons further revealed that the majority of the built classifiers did not distinguish the two cohorts significantly better than each other. (4) Conclusions: radiomics demonstrated discriminative ability in distinguishing patients with locally advanced HPV+ OPSCC who went on to develop distant metastasis after completion of definitive chemoradiation or radiation alone and may serve to risk stratify this patient population with the purpose of guiding the appropriate therapy.

Highlights

  • The incidence of oropharyngeal cancer has been increasing in the US due to the rising prevalence of human papillomavirus (HPV) [1]

  • The current study aimed to explore and evaluate the prognostic value of radiomics parameters derived from baseline computed tomography (CT) scans for the prediction of distant metastasis in patients with HPV+ oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive radiation or chemoradiation therapy

  • With respect to the treatment regimen, 122 (54%) patients underwent concurrent chemoradiotherapy (CRT), 59 (26%) received induction chemotherapy followed by CRT, 30 (14%) had radiation alone, and the remaining 14 (6%) were treated with induction chemotherapy followed by radiation alone

Read more

Summary

Introduction

The incidence of oropharyngeal cancer has been increasing in the US due to the rising prevalence of human papillomavirus (HPV) [1]. Treatment for locally advanced oropharyngeal cancer consists of primary surgery or chemoradiation therapy with no randomized data demonstrating a survival difference between modalities; definitive chemoradiation is preferred due to less morbidity [2,3]. Patients with locally advanced oropharyngeal cancer who receive definitive radiation therapy have a range of outcomes with a 5-year overall survival of between 56 and 89% [4] and a rate of distant metastasis between 8 and 15% at 3 years [5]. Finding HPV+ OPSCC patients with a favorable prognosis may allow for de-escalation of treatment and, thereby, reduce treatment-related morbidity. This is the goal of a number of current and recently completed HPV+

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call